The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.
 
Margaret Ottaviano
Honoraria - Novartis
Consulting or Advisory Role - Regeneron
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis/Pfizer; Pierre Fabre; Sun Pharma
 
Domenico Mallardo
No Relationships to Disclose
 
Ester Simeone
No Relationships to Disclose
 
Michele Del Vecchio
No Relationships to Disclose
 
Jacopo Pigozzo
No Relationships to Disclose
 
Laura Ridolfi
No Relationships to Disclose
 
Virginia Ferraresi
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Serb
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Novartis; PharmaMar; Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre
 
Mario Mandala
Honoraria - Bristol-Myers Squibb/Sanofi; LEO Pharma; MSD Oncology; Novartis; Pierre Fabre; Regeneron; Sanofi/Aventis
Consulting or Advisory Role - Bristol-Myers Squibb; LEO Pharma; MSD Oncology; Novartis; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Novartis (Inst)
 
Teresa Troiani
No Relationships to Disclose
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Miriam Paone
No Relationships to Disclose
 
Corrado Caraco
No Relationships to Disclose
 
Diana Giannarelli
No Relationships to Disclose
 
Nina Merchant
Employment - Medicenna
 
Arash Yavari
Employment - Weatherden
Stock and Other Ownership Interests - Imbria Pharmaceuticals
Consulting or Advisory Role - Medicenna
Research Funding - SBI Pharmaceuticals
 
Christian Blank
Stock and Other Ownership Interests - Immagene; SIGNATURE ONCOLOGY
Consulting or Advisory Role - Third Rock Ventures
Research Funding - NanoString Technologies (Inst)
Patents, Royalties, Other Intellectual Property - Wo 2021/177822a1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; ImCheck therapeutics; Immunocore; Incyte; Italfarmaco; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Moderna Therapeutics; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Medicenna (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre